The current market landscape features the presence of close to 150 companies that are engaged in the manufacturing of pharmaceutical polymers / medical polymers. Majority of the companies manufacture amino-based polymers including collagen, gelatin, poly-lysines, polyglutamic acid and poly-sarcosines. It is worth mentioning that around 15% of the players develop more than three compositions of pharmaceutical polymers / medical polymers.
The global medical polymers market size is estimated to grow from USD 20.80 billion in 2024 to USD 46 billion by 2035, representing a CAGR of 7.5% during the forecast period till 2035.
The pharmaceutical polymers / medical polymers market is highly fragmented, featuring the presence of established companies, as well as emerging start-ups. Around 35% of the companies engaged in this domain are headquartered in Asia-Pacific; of these, majority are mid-sized players (53%), followed by small firms (27%).
Presently, around 85 companies engaged in this domain manufacture synthetic polymers; this can be attributed to the several benefits offered by them, including resistance to chemicals, high flexibility, reasonable strength and versatility. Further, majority (75%) of the players manufacture thermoplastic polymers for the pharmaceutical / medical domain.
Pharmaceutical / Medical Polymers: Versatile Materials in the Healthcare Domain
Polymers are materials consisting of repetitive units of monomers that are bound together by strong covalent bonds. They are ubiquitous in our daily lives due to their favorable characteristics. Polymers can be divided into various categories, based on their backbone chain, degradation ability, molecular forces, source of origin, structure of monomer chain and morphology. Further, polymers are being employed in the pharmaceutical / medical sector for a myriad of applications, such as pharmaceutical excipients, medical devices (components and coatings), packaging systems for medications, tissue engineering and 3D printing.
It is important to mention that the manufacturing of pharmaceutical / medical polymers needs to be carried out in a controlled environment with strict adherence to regulatory guidelines in order to maintain the product quality and performance. A variety of novel polymers have also been developed that respond to external stimulus (electric or magnetic field, enzymes, pH, temperature and ultrasound waves), thereby modifying the release of the medication from the dosage form are targeting specific areas in the body. In addition, technological advancements in this domain have led to the development of biodegradable polymers; these polymers are resorbed in the body after fulfilling their function.
Driven by the rising demand for novel medical therapeutics and devices, and the ongoing efforts for the development of pharmaceutical polymers / medical polymers having improved biocompatibility and functionality, we believe that the pharmaceutical polymers / medical polymers market is likely to witness a steady growth over the coming years.
The increasing traction in the field of pharmaceutical polymers / medical polymers is evident from number of partnerships inked between stakeholder companies in the recent past. The maximum number of partnerships in the pharmaceutical / medical polymers domain were recorded in 2020 and 2022 (12 each). Product development agreements emerged as a prominent type of partnership model being adopted by stakeholders engaged in this domain.
In terms of intercontinental collaborations, maximum number of deals (23%) were signed between companies based in Europe and North America. Further, the maximum number of local as well as international agreements have been signed by companies based in the US.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/medical-polymers-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/
